Bacterial Vaccines Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type (Pertussis (Whooping Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines, Cholera Vaccines, Shigellosis Vaccines, Others), By Patient Age Group (Pediatric Vaccines (Infants, Children), Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines), By Distribution Channel (Government Agencies and Programs, Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, Others) , By Route of Administration (Injectable Vaccines, Oral Vaccines, Nasal Vaccines), By Region & Competition, 2020-2030F

Market Overview

Global Bacterial Vaccines Market was valued at USD 7.10 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.20% through 2030. Bacterial vaccines, also known as bacterial immunizations or bacterial vaccines, are a type of preventive medicine designed to stimulate the body's immune system to recognize and fight against specific bacterial pathogens. These vaccines are created using components of bacteria or inactivated bacterial cells to provide immunity against various bacterial infections. Bacterial vaccines are crucial for preventing a wide range of bacterial infections that can cause serious illnesses, complications, and even death. Common bacterial diseases prevented by vaccines include tetanus, diphtheria, pertussis, pneumonia, and meningitis.

Widespread vaccination with bacterial vaccines not only protects vaccinated individuals but also contributes to herd immunity. This indirectly protects those who cannot receive vaccines due to medical reasons, such as individuals with certain health conditions or weakened immune systems. Bacterial vaccines play a critical role in global health efforts, especially in low- and middle-income countries. Vaccination programs reduce the burden of bacterial diseases, improve child survival rates, and enhance overall public health. For instance, according to the Centers for Disease Control and Prevention (CDC) in 2025, outbreaks resulted in 75,968 reported human cases and 4,235 deaths, highlighting the significant impact of infectious disease spread.

The emergence of new and drug-resistant bacterial strains has highlighted the need for effective bacterial vaccines. Outbreaks of diseases like antibiotic-resistant tuberculosis and drug-resistant Staphylococcus aureus have spurred research and development efforts. Many governments worldwide run immunization programs that include bacterial vaccines. These programs aim to protect public health and reduce the burden of vaccine-preventable diseases. Pediatric vaccination programs, often including vaccines against bacterial diseases like diphtheria, pertussis, and Haemophilus influenzae type b (Hib), contribute significantly to the demand for bacterial vaccines. As the global population ages, there's a growing need for bacterial vaccines targeting older adults, who may be more susceptible to certain infections. Advances in vaccine technology, such as the development of conjugate vaccines and novel adjuvants, have improved the efficacy and safety of bacterial vaccines.

Key Market Drivers

Emerging Infectious Diseases

Emerging Infectious Diseases (EIDs) are diseases that have recently appeared in a population or have existed but are rapidly increasing in incidence or geographic range. These diseases often pose a significant threat to public health because they are novel, poorly understood, and may lack effective treatments. Bacterial EIDs can include diseases caused by antibiotic-resistant strains or previously unrecognized pathogens. Bacterial vaccines are crucial tools for the prevention and control of emerging bacterial infections. They provide a proactive approach to combat new threats by preparing populations with immunity against specific bacterial pathogens. In the event of an outbreak of an emerging bacterial infection, rapid vaccination campaigns can be implemented to contain the spread of the disease. This is particularly important in preventing large-scale epidemics or pandemics. For instance, according to WHO 2024, better vaccine use could cut antibiotic use by 2.5 billion doses annually, preventing deaths from antimicrobial resistance, reducing treatment costs, and curbing the spread of resistant infections.

Bacterial EIDs may be associated with antibiotic resistance, making traditional antibiotic treatments less effective. Bacterial vaccines can reduce the need for antibiotics by preventing infections in the first place, which is essential in addressing the global issue of antibiotic resistance. According to a 2024 article in Clinical Microbiology Reviews, vaccines and monoclonal antibodies are emerging as promising strategies to prevent healthcare-associated bacterial infections. These innovations aim to reduce infection rates, enhance patient safety, and combat antimicrobial resistance in healthcare settings. The emergence of diseases like COVID-19, which is caused by a novel coronavirus, has underscored the importance of public health preparedness. Developing and stockpiling bacterial vaccines for emerging threats is part of preparedness planning. Bacterial EIDs can have far-reaching global consequences, as demonstrated by the COVID-19 pandemic. Investments in vaccine research and development for emerging bacterial infections are seen as crucial for global health security. The recognition of EIDs as a significant global health concern often leads to increased funding for research into new vaccines and treatments. Government agencies, private foundations, and pharmaceutical companies may allocate resources to address these emerging threats. International collaboration among governments, research institutions, and vaccine manufacturers is often encouraged to develop and distribute vaccines for emerging bacterial infections. This collaboration can speed up vaccine development and deployment. This factor will help in the development of the Global Bacterial Vaccines Market.

Rising Demand of Pediatric Immunization

Many countries have established childhood immunization schedules that include a series of vaccines administered during infancy and early childhood. These schedules often include bacterial vaccines, such as those for diphtheria, tetanus, pertussis (DTaP), Haemophilus influenzae type b (Hib), and pneumococcal disease. Infants and young children are particularly vulnerable to certain bacterial infections. Vaccinating them during this critical period helps establish immunity before they are exposed to these diseases. Bacterial diseases like diphtheria, pertussis, and invasive pneumococcal disease can cause severe illness and complications in children. Bacterial vaccines are effective in preventing these diseases and their associated health risks. High vaccination rates among children not only protect vaccinated individuals but also contribute to herd immunity. This indirectly protects those who cannot receive vaccines for medical reasons, such as infants who are too young for certain vaccines or individuals with contraindications. Immunizing children against bacterial diseases has a long-term impact on public health. Preventing childhood infections reduces the overall burden of these diseases in the population, leading to fewer cases in adults and older individuals.

Some bacterial vaccines, like tetanus and diphtheria vaccines, require booster doses throughout life to maintain immunity. This ongoing need for vaccination contributes to the demand for bacterial vaccines. Public health authorities and governments often recommend or mandate the vaccination of children against specific bacterial diseases before entering school. These requirements drive vaccination rates. Bacterial vaccines administered to children undergo rigorous testing for safety and efficacy, leading to a high level of confidence in their effectiveness and safety among parents and healthcare providers. Hospitals, clinics, and healthcare providers are well-equipped to administer vaccines to children as part of childhood health programs. These programs are essential for ensuring that vaccines are readily available and accessible. International organizations, such as the World Health Organization (WHO) and UNICEF, support childhood vaccination programs in low- and middle-income countries, aiming to reduce child mortality and improve overall health. This factor will pace up the demand of the Global Bacterial Vaccines Market.

Increasing Government Immunization Programs

Governments typically establish and maintain vaccination schedules that specify when individuals should receive vaccines, including bacterial vaccines. These schedules provide a clear framework for healthcare providers and the public, ensuring that vaccines are administered at the recommended ages. For instance, in July 2023, the World Health Organization (WHO) prequalified MenFive®, the first conjugate vaccine protecting against the five most common meningococcal meningitis strains in Africa. Developed over 13 years by Serum Institute of India Pvt. Ltd. (SIIPL) and PATH, the project received crucial funding from the UK government’s Foreign, Commonwealth, and Development Office. Government immunization programs aim to prevent the spread of vaccine-preventable diseases, including bacterial infections. Vaccination reduces the incidence of these diseases, which is critical for public health. Governments actively promote and educate the public about the importance of vaccination. Public health campaigns and initiatives raise awareness about the risks of bacterial diseases and the benefits of vaccination, encouraging vaccine uptake. Government programs work to make vaccines accessible to all segments of the population, regardless of socioeconomic status. This includes offering vaccines at little to no cost and ensuring vaccines are available in both urban and rural areas. Many governments allocate funds to purchase and distribute vaccines, reducing the financial burden on individuals and families. Public financing of vaccines encourages higher vaccine coverage rates.

Some governments require children to receive specific vaccines, including bacterial vaccines, as a condition for school entry or attendance at daycare facilities. These requirements drive demand for vaccines. Government health agencies monitor disease incidence and outbreaks, enabling rapid response to disease threats. When outbreaks occur, vaccination campaigns may be initiated to contain the spread of the disease. In the event of public health emergencies, such as epidemics or pandemics, governments may mobilize vaccination efforts to protect the population. This includes stockpiling vaccines for rapid deployment. Governments regulate vaccine safety and efficacy through agencies like the U.S. Food and Drug Administration (FDA) in the United States. This oversight helps ensure that vaccines meet rigorous safety and efficacy standards. Governments often collaborate with international organizations to support vaccination programs in low- and middle-income countries. These initiatives help improve vaccine access and distribution on a global scale. Government endorsement and support for vaccines help build public trust. When vaccines are recommended or required by governments, individuals are more likely to accept vaccination. This factor will accelerate the demand of the Global Bacterial Vaccines Market.

Download Free Sample Report

Key Market Challenges

Vaccine Hesitancy

Vaccine hesitancy refers to the reluctance or refusal of individuals or communities to accept vaccines, despite the availability of vaccination services. This hesitancy can manifest for various reasons, including safety concerns, misinformation, and distrust of vaccines and healthcare systems. Vaccine hesitancy can lead to lower vaccination rates, which means that fewer individuals are protected against bacterial infections. This can result in pockets of susceptible individuals within a community, increasing the risk of disease outbreaks. Lower vaccine coverage due to hesitancy reduces the level of herd immunity within a population. This not only puts unvaccinated individuals at risk but also makes it easier for bacterial diseases to spread within the community. Vaccine hesitancy can impede public health efforts to control bacterial infections. Diseases that were once well-controlled can experience resurgence when vaccine coverage declines. A rise in vaccine-preventable diseases due to hesitancy can strain healthcare systems, leading to increased healthcare costs associated with treating these diseases and their complications. Governments and healthcare organizations must allocate resources to combat vaccine hesitancy through public health campaigns, educational initiatives, and outreach efforts. These resources could be used elsewhere if hesitancy was not a factor. Reduced demand for bacterial vaccines may affect funding for research and development of new vaccines and improvements to existing ones. Pharmaceutical companies may be less motivated to invest in vaccine development if there is lower demand. The spread of misinformation and vaccine-related myths on social media platforms can contribute to vaccine hesitancy. False information can erode public trust in vaccines and healthcare providers. Safety concerns, whether founded in evidence or not, can lead to hesitancy. High-profile vaccine safety scares can have lasting effects on public perception.

Antibiotic Resistance

Antibiotic resistance refers to the ability of bacteria to resist the effects of antibiotics, making infections caused by these bacteria more challenging to treat. As bacteria become increasingly resistant to antibiotics, the effectiveness of traditional antibiotic treatments diminishes. This makes it imperative to explore alternative approaches to combat bacterial infections, including vaccines. The rise of antibiotic-resistant bacterial strains underscores the need for non-antibiotic interventions, such as vaccines, to prevent infections. Vaccines can provide protection against bacterial diseases without relying on antibiotics. Antibiotic-resistant bacterial infections are often more severe and difficult to treat. This can lead to longer hospital stays, increased healthcare costs, and higher mortality rates. Vaccination can help prevent these infections from occurring in the first place. The economic burden of antibiotic resistance is substantial, with increased healthcare costs, lost productivity, and additional expenses associated with managing drug-resistant infections. Bacterial vaccines can help reduce these economic burdens by preventing infections. As antibiotic resistance spreads, healthcare providers have fewer treatment options for bacterial infections. Vaccination can help preserve the effectiveness of existing antibiotics by preventing the need for treatment in the first place. The overuse and misuse of antibiotics have contributed to the development of multidrug-resistant bacterial strains. These strains are resistant to multiple classes of antibiotics, making them particularly challenging to treat. Vaccines can target these bacteria before they become resistant.

Key Market Trends

Pipeline Developments

Pharmaceutical companies and research institutions are actively working on expanding their portfolio of bacterial vaccines. This includes developing vaccines for a wide range of bacterial pathogens responsible for various infectious diseases. The emergence of new bacterial pathogens or the reemergence of existing ones often prompts the development of vaccines to address these threats. Recent examples include vaccine development efforts in response to antibiotic-resistant strains of bacteria. Advances in vaccine technology, including the use of novel adjuvants, recombinant DNA technology, and conjugate vaccine platforms, are driving innovation in bacterial vaccine development. These technologies can improve vaccine efficacy and safety. Research is focused on developing highly targeted vaccines that are effective against specific bacterial strains or serotypes. Precision in vaccine design is important for combating antibiotic-resistant bacteria. Some pipeline developments involve multivalent vaccines that target multiple bacterial strains or serotypes in a single vaccine formulation. This can simplify vaccination schedules and improve coverage. International organizations and governments are supporting vaccine research and development for bacterial diseases that disproportionately affect low- and middle-income countries. These initiatives are aimed at reducing global health disparities. Recent pandemics, such as COVID-19, have highlighted the importance of vaccine development for emerging infectious diseases, including those caused by bacterial pathogens. Preparedness efforts include research into rapid vaccine development platforms.

Segmental Insights

Vaccine Type Insights

In 2022, the Global Bacterial Vaccines Market largest share was held by Diphtheria Vaccines segment and is predicted to continue expanding over the coming years. Diphtheria vaccines, often administered as part of combination vaccines, are a crucial component of childhood immunization schedules in many countries. These vaccines are typically given to infants and young children, contributing to high vaccination rates. Diphtheria is a potentially life-threatening bacterial infection that primarily affects the respiratory system. Vaccination against diphtheria has been highly effective in reducing the incidence of the disease, making it a public health priority. Diphtheria vaccines are commonly administered in combination with other vaccines, such as tetanus and pertussis vaccines, as part of a comprehensive approach to childhood immunization. This convenience encourages higher vaccination coverage. High vaccination coverage against diphtheria not only protects vaccinated individuals but also contributes to herd immunity, reducing the overall circulation of the bacterium in the population.

Route of Administration Insights

In 2024, the Global Bacterial Vaccines Market largest share was held by Injectable Vaccines segment in the forecast period and is predicted to continue expanding over the coming years.  Injectable vaccines, including bacterial vaccines, have a long history of effectiveness and safety. This established track record contributes to the preference for injectable vaccines, as they are known to be reliable in generating immune responses. Injectable vaccines allow for precise dosing and targeted delivery of antigens. This is particularly important for bacterial vaccines, as it ensures that the immune system is exposed to the specific components of the bacteria needed to trigger a protective response. Many bacterial vaccines are protein-based, and injectable vaccines provide a stable and controlled environment for these proteins, minimizing the risk of degradation and ensuring the vaccine's efficacy. Some bacterial vaccines require booster shots to maintain long-term immunity. Injectable vaccines are well-suited for administering booster doses, as they offer a convenient and consistent method for delivering additional doses of the vaccine.

Download Free Sample Report

Regional Insights

The North America region dominated the Global Bacterial Vaccines Market in 2024. North America, particularly the United States and Canada, boasts advanced healthcare infrastructure with well-established vaccine distribution networks. This infrastructure facilitates the research, development, manufacturing, and distribution of vaccines. North America is home to some of the world's largest pharmaceutical companies with substantial resources for vaccine research and development. These companies often lead the way in creating and distributing bacterial vaccines. The region has high healthcare spending, which allows for substantial investments in vaccine development and deployment. This includes both government spending and private sector investments. North America has a robust biomedical research ecosystem, including academic institutions, research organizations, and biotechnology companies. These entities are involved in cutting-edge vaccine research and development.

Recent Developments

• On April 13, 2023, the University of Oxford and Serum Institute of India, using Novavax’s adjuvant technology, manufactured and scaled up the R21/Matrix-M malaria vaccine, which was licensed for use in Ghana by the country's Food and Drugs Authority.
• On October 6, 2023, Amgen Inc., a leading pharmaceutical company, announced the completion of its acquisition of Horizon Therapeutics plc. This strategic move aims to expand Amgen’s reach in addressing serious illnesses globally, enhancing treatment options and improving patient care through innovative therapies and a strengthened pharmaceutical portfolio.
• On October 5, 2023, Emergex Vaccines Holding Limited partnered with Saudi Arabia’s Vaccine Industrial Company (VIC) to advance T cell-priming immune candidates for infectious diseases. The collaboration includes government-supported Phase II/III trials for dengue, coronavirus, influenza, yellow fever, and related treatments.
• On February 15, 2023, Bavarian Nordic A/S announced an agreement with Emergent BioSolutions Inc. to acquire two travel vaccines, Vivotif for typhoid fever and Vaxchora for cholera, along with a Phase 3 Chikungunya vaccine candidate, expanding its infectious disease portfolio.
• In August 2019, the world's largest over the counter (OTC) company with strong iconic brands has been created because of Pfizer Inc. and GlaxoSmithKline plc's joint venture, which brought together the parties' respective consumer healthcare companies. In accordance with the terms of the deal, Pfizer controls 32% of the joint venture's stock while GSK has 68%, as was previously reported. CEO Brian McNamara will oversee the merged company, which will do business internationally as GSK Consumer Healthcare. With leading positions in the fields of respiratory, vitamins, minerals, and supplements, therapeutic oral health, and pain treatment, the combined brand portfolio makes up the largest OTC company in the world.
• In September 2023, the first independent CDMO site for vaccines has been opened in Suzhou, China, by WuXi Vaccines, a renowned contract development and manufacturing organisation (CDMO) with a focus on vaccine discovery, development, and manufacture. With end-to-end services for a variety of vaccines, the opening will increase the capacity for producing drug substances and drug products. This will speed up the project timelines for global clients, from process and drug product development to clinical-scale drug substance (DS) and small- to medium-scale sterile drug product (DP) manufacturing. Its DS production area has two cell culture lines, one purification line, and a reserved capacity for 2,000L of output, allowing DS production sizes from 50L to 1,000L. An automatic vial washing, sterilising, filling, and capping line that can support the clinical manufacturing of both liquid and lyophilized products is available at the DP facility.

Key Market Players

• Pfizer Inc.
• GSK plc
• Novartis AG
• Mylan N.V.
• Sanofi SA
• Boehringer Ingelheim International GmbH.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Bharat Biotech International Ltd
• Serum Institute of India Pvt. Ltd

Report Scope:

In this report, the Global Bacterial Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•     Bacterial Vaccines Market, By Vaccine Type:

o   Pertussis (Whooping Cough) Vaccines

o   Tetanus Vaccines

o   Diphtheria Vaccines

o   Pneumococcal Vaccines

o   Meningococcal Vaccines

o   Typhoid Vaccines

o   Tuberculosis (TB) Vaccines

o   Cholera Vaccines

o   Shigellosis Vaccines

o   Others

•   Bacterial Vaccines Market, By Patient Age Group:

o   Pediatric Vaccines (Infants, Children)

o   Adolescent Vaccines

o   Adult Vaccines

o   Geriatric Vaccines

•   Bacterial Vaccines Market, By Distribution Channel:

o   Government Agencies and Programs

o   Hospitals and Clinics

o   Retail Pharmacies

o   Online Pharmacies

o   Others

•     Bacterial Vaccines Market, By Route of Administration:

o   Injectable Vaccines

o   Oral Vaccines

o   Nasal Vaccines

• Bacterial Vaccines Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Vaccines Market.

Available Customizations:

Global Bacterial Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Bacterial Vaccines Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com